4.3 Article

Prevention of episodic migraine with topiramate: a prospective 24-week, open-label, flexible-dose clinical trial with optional 24 weeks follow-up in a community setting

Related references

Note: Only part of the references are listed.
Article Clinical Neurology

Body mass index and headaches: findings from a national sample of US adults

E. S. Ford et al.

CEPHALALGIA (2008)

Review Clinical Neurology

Anticonvulsants in migraine prophylaxis: a Cochrane review

W. M. Mulleners et al.

CEPHALALGIA (2008)

Article Pharmacology & Pharmacy

Weight change associated with the use of migraine-preventive medications

Frederick R. Taylor

CLINICAL THERAPEUTICS (2008)

Review Clinical Neurology

Update on the prophylaxis of migraine

Markus Schuerks et al.

CURRENT TREATMENT OPTIONS IN NEUROLOGY (2008)

Article Clinical Neurology

Expert opinion: Beta-blockers for migraine

Randolph W. Evans et al.

HEADACHE (2008)

Article Clinical Neurology

Time course of adverse events most commonly associated with topiramate for migraine prevention

M. J. A. Lainez et al.

EUROPEAN JOURNAL OF NEUROLOGY (2007)

Article Clinical Neurology

Cost of disorders of the brain in Europe

P Andlin-Sobocki et al.

EUROPEAN JOURNAL OF NEUROLOGY (2005)

Article Clinical Neurology

Topiramate in migraine prevention - Results of a large controlled trial

SD Silberstein et al.

ARCHIVES OF NEUROLOGY (2004)

Article Medicine, General & Internal

Topiramate for migraine prevention - A randomized controlled trial

JL Brandes et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)